FMP
NASDAQ
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
13.28 USD
0.49 (3.69%)
Valuation Date:
Apr 29, 2024 4:00 PM
Share Price on Valuation Date
$13.28
Stock Beta
0.681908
Shares Outstanding
49700830